Page 1

company announcement Financial report for the period 1 January 2021 to 30 September 2021 3 November 2021 Novo Nordisk's net profit increased by 12 % in the first nine months of 2021 Operating profit increased by 5 % in Danish kroner and by 12 % at constant exchange rates ( CER ) . Sales increased by 8 % in Danish kroner and by 13 % at CER to DKK 102.5 billion . Sales in International Operations increased by 10 % in Danish kroner ( 13 % at CER ) , and sales in North America Operations increased by 6 % in Danish kroner ( 13 % at CER ) . ● Sales within Diabetes and Obesity care increased by 10 % in Danish kroner to DKK 88.0 billion ( 15 % at CER ) , driven by GLP - 1 growth of 24 % in Danish kroner ( 30 % at CER ) reflecting the uptake of Ozempic® and Rybelsus® . Obesity care grew by 41 % in Danish kroner ( 49 % at CER ) and Biopharm sales remained unchanged in Danish kroner ( increased by 4 % at CER ) . Sales in the third quarter increased by 15 % in Danish kroner ( 15 % at CER ) compared to the third quarter of 2020. Sales growth was driven by diabetes GLP - 1 growth of 30 % in Danish kroner ( 31 % at CER ) and Obesity care growth of 79 % in Danish kroner ( 82 % at CER ) reflecting market expansion and the launch of Wegovy ™ in the US . • Within R & D , Novo Nordisk initiated phase 3 development with both oral semaglutide 50 mg for the treatment of obesity and with ziltivekimab in cardiovascular disease during the third quarter . On 29 October , the 2021 outlook was raised with sales growth and operating profit growth now both expected to be 12-15 % at CER . Sales and operating profit growth reported in Danish kroner is now expected to be 3 and 4 percentage points lower than at CER , respectively . The ongoing share buyback programme is expanded by DKK 2.0 billion to DKK 20 billion . PROFIT AND LOSS DKK million Net sales Operating profit Net profit Diluted earnings per share ( in DKK ) * CER : Constant exchange rates ( average 2020 ) . 9M 2021 Novo Nordisk A / S Investor Relations novo nordisk 102,467 45,010 Novo Allé 2880 Bagsværd Denmark 36,865 15.98 9M 2020 94,808 42,948 32,820 14.00 Growth as reported 8 % 5 % 12 % 14 % Growth at CER * Lars Fruergaard Jørgensen , president and CEO : " We are very pleased with the sales growth in the first nine months of 2021 which has enabled us to raise our outlook for the full year . The growth is driven by all geographical areas and by all therapy areas , in particular by accelerated growth of our portfolio of GLP - 1 treatments for diabetes and obesity . In the US , the initial demand for Wegovy ™ has significantly exceeded our expectations , underscoring the high unmet need for people living with obesity . With the initiation of two phase 3 programmes in the third quarter , we continue to expand our late stage clinical pipeline . " 13 % 12 % On 3 November 2021 at 13.00 CET , corresponding to 08.00 AM EDT , an earnings call will be held . Investors will be able to listen in via a link on novonordisk.com , which can be found under Investors ' . Telephone : +45 4444 8888 www.novonordisk.com N / A N / A CVR Number : 24 25 67 90 Company announcement No 66 / 2021